Targeted adenoviral gene transfer to the kidney

Slides:



Advertisements
Similar presentations
Volume 62, Pages S12-S22 (December 2002)
Advertisements

Volume 67, Issue 5, Pages (May 2005)
Effects of hypoxia on renin secretion and renal renin gene expression
Renal manifestations in Fabry disease and therapeutic options
Anemia management in chronic kidney disease
Effects of hypoxia on renin secretion and renal renin gene expression
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
The Case ∣ Acute renal failure and anemia
Yihan Wang, Michael A. Shia, Thomas G. Christensen, Steven C. Borkan 
Ligation of CD31 (PECAM-1) on Endothelial Cells Increases Adhesive Function of vβ3 Integrin and Enhances β1 Integrin-Mediated Adhesion of Eosinophils.
Volume 56, Issue 1, Pages (July 1999)
Volume 60, Issue 1, Pages (July 2001)
Volume 72, Issue 1, Pages (July 2007)
c-myc antisense oligonucleotide treatment ameliorates murine ARPKD
Progression of renal failure and hypertensive nephrosclerosis
Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells1
Volume 58, Issue 4, Pages (October 2000)
Thomas E. Arnold, MD, Dmitri Gnatenko, PhD, Wadie F. Bahou, MD 
Volume 61, Issue 1, Pages S68-S72 (January 2002)
TGF-β isoforms in renal fibrogenesis
Volume 77, Issue 1, Pages 6-8 (January 2010)
Gene electrotransfer: Potential for gene therapy of renal diseases
Francesco Paolo Schena  Kidney International 
Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells1  Gunter Wolf, Regine Schroeder, Fuad N.
Volume 69, Issue 1, Pages (January 2006)
New generation adenoviral vectors improve gene transfer by coxsackie and adenoviral receptor-independent cell entry  Paul N. Reynolds, David T. Curiel 
George A. Kaysen, Burl R. Don
Infection and chronic allograft dysfunction
Comorbidity and confounding in end-stage renal disease
Volume 61, Issue 1, Pages S3-S8 (January 2002)
Alisa K. Hughes, Peter K. Stricklett, Doug Schmid, Donald E. Kohan 
Volume 15, Issue 9, Pages (September 2007)
Volume 70, Issue 11, Pages (December 2006)
Aquaporin gene delivery to kidney
Volume 71, Issue 6, Pages (March 2007)
Fructose intake as a risk factor for kidney stone disease
Volume 62, Pages S12-S22 (December 2002)
In vivo gene transfer to kidney by lentiviral vector
Volume 5, Issue 6, Pages (June 2002)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 80, Issue 5, Pages (September 2011)
Nephrology in Latin America, with special emphasis on Brazil
AGEs in foods: Do they play a role in uremia?
Adenovirus-mediated gene transfer to renal glomeruli in rodents
Unilateral renal cystic disease
Volume 76, Issue 1, Pages 6-7 (July 2009)
International Society of Nephrology
Volume 55, Issue 6, Pages (June 1999)
Volume 61, Issue 5, Pages (May 2002)
Polarity of α-galactosidase A uptake by renal tubule cells
Peritoneal dialysis in Mexico
Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program  Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.
Clinical benefits of slowing the progression of renal failure
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Volume 83, Issue 4, Pages (April 2013)
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Volume 56, Issue 1, Pages (July 1999)
Volume 54, Issue 6, Pages (January 1998)
Charles A. Herzog  Kidney International 
Is complement a target for therapy in renal disease?
Volume 74, Issue 9, Pages (November 2008)
T cells and T-cell receptors in acute renal failure
Rachel Maddox Schek, Scott J Hollister, Paul H Krebsbach 
c-myc antisense oligonucleotide treatment ameliorates murine ARPKD
Jason G. Umans, Debra Salvi, Patrick T. Murray, Mark E. Wylam 
Morphology of the heart and arteries in renal failure
Development and differentiation of endothelium
Histological diagnosis of renal osteodystrophy
Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease?  Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger  Kidney.
Presentation transcript:

Targeted adenoviral gene transfer to the kidney Glenn A. McDonald  Kidney International  Volume 61, Issue 1, Pages S42-S46 (January 2002) DOI: 10.1046/j.1523-1755.2002.0610s1042.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Specificity of AdZ and AdZ; F(RGD) transduction on endothelial cells. (A) Monolayers of HuVECs and human lung epithelial cells (A549) in 24-well collagen-coated plates were incubated with 107, 108, or 109 virus particles of AdZ or AdZ.F(RGD) for 60 minutes followed by removal of unbound particles. The cells were cultured for 48 hours followed by determination of β-galactosidase activity for each sample using a chemiluminescent assay. Results are the average of duplicate samples. (B) Monolayers of HuVECs in 24-well collagen-coated plates were preincubated for 30 minutes with purified recombinant F5K or F5K(RGD) protein. The cells were further incubated with 109 virus particles of AdZ or AdZ.F(RGD) for an additional 60 minutes, followed by removal of unbound particles. The cells were cultured for 48 hours followed by determination of β-galactosidase activity for each sample using a chemiluminescent assay. Results are the average of duplicate samples. Kidney International 2002 61, S42-S46DOI: (10.1046/j.1523-1755.2002.0610s1042.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Comparison of in vivo transduction of AdZ and AdZ.F(RGD) with low-dose renal artery infusion. Low-dose (1 × 1011 particles) AdZ (N = 3) and AdZ.F(RGD) (N = 4) was infused into the left renal artery and allowed to incubate in the left kidney for 45 minutes at 4°C. Both the left and the right kidney was harvested at 48 hours and stained for β-galactosidase activity. The right kidney serves as an internal negative control. (A) Gross slice of the left kidney with AdZ (×3). (B) Gross slice of the left kidney infused with AdZ.F(RGD) (×3). Kidney International 2002 61, S42-S46DOI: (10.1046/j.1523-1755.2002.0610s1042.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Comparison of in vivo transduction of AdZ and AdZ.F(RGD) with standard dose renal artery infusion. Standard dose (8 × 1011 particles) AdZ (N = 3) and AdZ.F(RGD) (N = 4) was infused into the left renal artery and allowed to incubate in the left kidney for 45 minutes at 4°C. Kidneys were harvested at 48 hours and stained for β-galactosidase activity. The right kidney serves as an internal negative control. (A) A gross slice of the left kidney infused with AdZ (×3). (B) A gross slice of the left kidney infused with AdZ.F(RGD) (×3). (C) Macroscopic view of a 12 μm histologic section of AdZ (×3.2). (D) Macroscopic view of 12 μm histologic section of AdZ.F(RGD) (×3.2). (E) Microscopic view of a 12 μm histologic section of AdZ (×25). (F) Microscopic view of a 12 μm histologic section of AdZ.F(RGD) (×25). (G) High-power microscopic view of a 6 μm histologic section of AdZ.F(RGD) (×40). Kidney International 2002 61, S42-S46DOI: (10.1046/j.1523-1755.2002.0610s1042.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 In vivo competition assay with RGD and RGE peptides. Soluble RGD and RGE peptides (1.0 mg/mL) were coinfused with 8 × 1011 particles of AdZ.F(RGD) prior to renal artery infusion. (A) Left kidney β-galactosidase staining in the left kidney following coinfusion of the RGD peptide (×25). (B) Coinfusion of the control RGE peptide (×25). Kidney International 2002 61, S42-S46DOI: (10.1046/j.1523-1755.2002.0610s1042.x) Copyright © 2002 International Society of Nephrology Terms and Conditions